Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 13/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.53 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.53 |
| ▸ | PLK4 | O00444 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.53 |
| ▸ | TYK2 | P29597 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716235 | 1.00 | CHEK1 (0.64) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL3713764 | 0.83 | CHEK1 (0.68) | CHEK1KDRFGFR1LCKCDK2 | |
| SCHEMBL3713767 | 0.83 | CHEK1 (0.68) | CHEK1KDRFGFR1LCKCDK2 | |
| SCHEMBL29531075 | 0.81 | CHEK1 (0.67) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL14539159 | 0.81 | CHEK1 (0.67) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL28884514 | 0.81 | CHEK1 (0.67) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL28884515 | 0.81 | CHEK1 (0.67) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL5498220 | 0.81 | KDR (0.69) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL5498217 | 0.81 | CHEK1 (0.67) | CHEK1KDRFGFR1CSF1RPDGFRB | |
| SCHEMBL13654206 | 0.80 | KDR (0.54) | CHEK1KDRFGFR1CSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| CN-101970426-A | Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIV HEALTH NETWORK | 2011-02-09 | — | — | CN | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | CHEK1 97/4885KDR 679/4885FGFR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.